230 results on '"Gilkes, Amanda"'
Search Results
2. Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
3. A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
4. Overlapping features of therapy-related and de novo NPM1-mutated AML
5. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
6. Unified classification and risk-stratification in Acute Myeloid Leukemia
7. RUNX3 overexpression inhibits normal human erythroid development
8. Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients
9. Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML
10. Molecular MRD status and outcome after transplantation in NPM1-mutated AML
11. Post induction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission
12. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
13. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission
14. P484: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT TRIAL
15. S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL
16. P503: A RANDOMISED TRIAL OF MOLECULAR MONITORING VERSUS STANDARD CLINICAL CARE IN YOUNGER ADULTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI AML17 AND AML19 STUDIES
17. P546: MACHINE LEARNING AND RESPONSE TO INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
18. S131: A RANDOMISED ASSESSMENT OF THE SEQUENTIAL ADDITION OF THE KINASE INHIBITOR QUIZARTINIB TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKAEMIA (AML) PATIENTS: RESULTS FROM THE NCRI AML18 TRIAL
19. Postinduction molecular MRD identifies patients with NPM1AML who benefit from allogeneic transplant in first remission
20. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase
21. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
22. Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia
23. Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome
24. FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial
25. Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study
26. Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial
27. Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1m Patients Achieving MRD-Negative CR after Intensive Induction
28. A Randomized Comparison of the Fractionated Versus Single Dose Schedule of Gemtuzumab Ozogamicin at Induction with Determinants of Benefit for Older AML Patients: UK NCRI AML18 Trial Results
29. Protein Kinase C Epsilon Overexpression Is Associated With Poor Patient Outcomes in AML and Promotes Daunorubicin Resistance Through p-Glycoprotein-Mediated Drug Efflux
30. Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia
31. RARα-PLZF Overcomes PLZF-Mediated Repression of CRABPI, Contributing to Retinoid Resistance in t(11;17) Acute Promyelocytic Leukemia
32. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (vol 13, 2, 2022)
33. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia
34. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA
35. High Sensitivity Detection of FLT3-ITD Measurable Residual Disease By Deep Sequencing Prior to Hematopoietic Cell Transplant Is Highly Prognostic for Outcome in Acute Myeloid Leukemia
36. MRD Directed Treatment Intensification with Either FLAG-Ida or DA-Cladribine Improves Survival in Older AML Patients: Results from the NCRI AML18 Randomised Trial
37. Influence of Bone Marrow Blast Enumeration and Co-Occurring Myelodysplasia Related Gene Mutations in NPM1-Mutated Myeloid Malignancies
38. The Benefit of Allogeneic Transplant in 1 st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies
39. The Natural History of NPM1MUT Measurable Residual Disease (MRD) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia (AML)
40. Alteration of Metabolic Conditions Impacts the Regulation of IGF-II/H19 Imprinting Status in Prostate Cancer
41. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases
42. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia
43. Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia
44. FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1and FLT3mutated Subgroups. Results from the UK NCRI AML19 Trial
45. Outcomes in Relapsed/Refractory Patients with FLT3-ITD Mutated AML Are Poor When Treated with Non-Targeted Therapy with a Potential Role for Stem Cell Transplantation: Results from the NCRI AML Trials
46. Molecular, clinical, and therapeutic determinants of outcome in NPM1mutated AML
47. The Benefit of Allogeneic Transplant in 1 stComplete Remission in NPM1Mutated AML with or without FLT3ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies
48. Significance of Blast CD33 Expression for Effect of Gemtuzumab Ozogamicin at Different Doses in Adult Acute Myeloid Leukemia: Results from the UK NCRI AML16/17 Trials
49. A Knowledge-Based Approach for Clinical Annotation of Oncogenic Variants to Support Patient-Tailored Diagnosis in Myeloid Disease
50. The Natural History of NPM1MUTMeasurable Residual Disease (MRD) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia (AML)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.